Clinical Trial Update: Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is recruiting to evaluate first-line sequential AG and mFOLFOX with serplulimab and bevacizumab versus AG chemotherapy alone in advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Abraxane (nab-paclitaxel) (nab-paclitaxel)
• Bevacizumab (bevacizumab)
• Gemcitabine (Gemcitabine)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• Serplulimab (serplulimab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Non-Resectable Pancreas Carcinoma | Phase 3 | Status: RECRUITING